modelG03AA08

Diagram of G03AA08

Extends from Pharmacokinetic.Models.PK_1C_enteral.

Information

name:MedroxyprogesteroneAndEthinylestradiol
ATC code:G03AA08
route:oral
compartments:1
dosage:6mg
volume of distribution:55L
clearance:3.5L/h
other parameters in model implementation

Medroxyprogesterone and ethinylestradiol is a combined oral contraceptive containing the progestin medroxyprogesterone acetate and the estrogen ethinylestradiol. This combination was previously used for hormonal contraception and regulation of menstrual disorders. Currently, it is not widely used or approved in most countries, having been largely replaced by other contraceptive combinations.

Pharmacokinetics

Estimated pharmacokinetic parameters for healthy adult women based on published pharmacokinetics of individual components (medroxyprogesterone acetate and ethinylestradiol) as no specific studies of the combination were identified.

References

  1. Mohamed, MF, et al., & Othman, AA (2019). The JAK1 Inhibitor Upadacitinib Has No Effect on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol: A Study in Healthy Female Subjects. Journal of clinical pharmacology 59(4) 510–516. DOI:10.1002/jcph.1350 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30500075

  2. Darwish, M, et al., & Grasela, T (2014). A comparison of the pharmacokinetic profile of an ascending-dose, extended-regimen combined oral contraceptive to those of other extended regimens. Reproductive sciences (Thousand Oaks, Calif.) 21(11) 1401–1410. DOI:10.1177/1933719114526472 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24647707

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.TransferRateka (from PK_1C_enteral)0.016666666666666666first order absorption rate
Modelica.Units.SI.TimeTlag (from PK_1C_enteral)600delay between oral administration and absorption (default 10min)

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)